The interleukin 2 receptor ~ chain (IL-21~) is preferentially expressed in natural killer (NK) cells, but is not detected in a majority of resting T and B cells. We recently established a novel monoclonal antibody (mAb) to murine IL-2RB and examined in vivo the effect of the mAb in mice. We found that intraperitoneal injection of the anti-IL-2RB mAb into adult mice resulted in a selective in vivo elimination of splenic NK function in various mouse strains. The reduction of NK cell function is associated with complete disappearance of NKI.1 + cells in C57BL/6 mice. Other lymphocyte subsets in the thymus and spleen were uncompromised. T cell function was not affected by the mAb treatment as judged by allogeneic cytotoxic T cell induction. The single injection of anti-IL-2RB mAb caused a long-term elimination of splenic NK cells, lasting for at least 5 wk. We also found that NK and/or NK precursor cells become susceptible to the mAb treatment only after birth, suggesting that functional maturation of NK cells in terms of IL-2RB expression is a later event in the course of NK cell development. The use of the anti-IL-2RB mAb will be useful in defining the physiological role of NK cells in host defense as well as dissecting their developmental pathway in vivo.
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N
'K cells are large granular lymphocytes (LGL) that express MHC-nonrestricted cytotoxic activity. Several lines of evidence indicate that the NK cell is responsible for eradication of tumor cells (1, 2) and vitally infected cells (3), however, roles of NK cells in immune defense remain to be fully elucidated.
IL-2 is a major growth factor for mature NK cells (4, 5) . Freshly isolated NK cells preferentially express IL-2RB, through which IL-2 plays a pivotal role in proliferation and induction of cytolytic activity (6) . IL-2RB is also expressed in other cell types, such as fetal T cells expressing V'r5 TCR (7) and a subset of adult CD8 + T cells (8) . We recently reported that in utero treatment of mice with a neutralizing mAb against IL-2RB completely and selectively abrogates development of the Thy-1 + dendritic epidermal cell (Thy-1 + dEC), which is a descendant of the IL-2RB + V3'5 TCR + cells (7) .
In the present study, we report that postnatal treatment of mice with the anti-IL-2RB mAb (a single intraperitoneal injection) causes a long-lasting selective elimination of NK cells. We also report that NK cells and/or NK precursor cells become sensitive to anti-IL-2RB mAb treatment after birth.
Materials and Methods
M/c~ Pregnant or male C57BL/6 and male C3H/He mice were purchased from Shizuoka Laboratory Animal Center (Hamamatsu, Japan). Institute of Cancer Research (ICR) nu/nu mice and SCID (C.B17 scid/scid) mice were obtained from Charles River Japan Inc. Antibody Treatment. Adult mice were treated intraperitoneally with 1 mg of anti-IL-2RB mAb TM-B1 (rat IgG2b) or control normal rat IgG (Sigma Chemical Co., St. Louis, MO) in 500/~1 of PBS as indicated. In a separate series of experiments, antibody injection was performed by two different protocols as follows. For in utero treatment, pregnant C57BL/6 mice were given intraperitoneal injection of I mg of anti-Ib2RB mAb daily from day 12 of gestation until birth as previously described (7) . For postnatal treatment, neonatal mice were given a subcutaneous injection of ,'~50/~g of anti-Ib2RB mAb three times a week, which was continued until analysis. Injection volume was "~50/~l/d. Normal rat IgG was injected as a negative control in some experiments.
Cell-mediated Cytotoxicity. Cytotoxic activity of NK cells was measured in a standard 4-h SXCr release assay (16) . Briefly, 5 x 103 52Cr-labeled YAC-1 cells were mixed with a varied number of spleen cells and incubated for 4 h in 200/zl of the culture medium (RPMI 1640 [ICN Biomedicals Inc., Costa Mesa, CA], 10% FCS [Cell Culture Laboratories, Cleveland, OH], 10 mM Hepes, 2 mM r-glutamine, 50 #M 2-ME, 100 U/ml penicillin, and 100/zg/ml streptomycin). Nylon wool-nonadherent spleen cells (17) were used for a NK source in C57BL/6 mice. After incubation, the radioactivity in 100 #I of supernatant was measured and percent cytotoxicity was determined. Primary CTL were induced by culture of C57BL/6 mouse spleen cells (5 x 1@) with mitomycin C-treated BALB/C mouse spleen cells (2.5 x 106) for 4 d in 2 mt of the culture medium. The cytotoxicity was determined as above by using P815 (H-2a), RL-malel (H-2a), or EL-4 (H-2 b) cells as targets.
Flow Cytometry. Immunofluorescence and flow cytometric analysis was performed as described (8) . At least 10,000 cells per sample were analyzed on EPICS-CS or EPICS-Elite flow cytometers (Coulter Electronics, Hialeah, FL).
Results and Discussion

Selective Long-Term Elimination of NK Cells by an Anti-IL-2R~ mAb In Viwx
To evaluate the functional importance of IL-2R,8 expression in NK cells in vivo, adult mice were given an intraperitoneal injection of a function-blocking anti-IL-2RB mAb TM-B1 (8) . NK activity in the spleen of antibody-treated mice was determined by using YAC-1 cells as a target. We found that an intraperitoneal injection with anti-IL-2RB mAb abrogated cytolytic activity of NK cells in various mouse strains, including C3H/He, C57BL/6, ICR nu/nu, and SCID mice (Fig. t) . As shown in Fig. 1 , C and D, a single intraperitoneal injection of t mg of anti-IL-2R43 mAb is sufficient for a profound reduction of NK activity in vivo.
Flow cytometric analysis was performed to determine whether the reduction of NK activity was caused by functional inactivation or elimination of NK cells by using C57BL/6 mice. As shown in Fig. 2 , NK cells marked by expression of NKI.1 alloantigen were almost completely depleted in anti-IL-2RB-treated mice (Fig. 2 B) , whereas they were readily detected in control IgG-treated mice (Fig. 2 A) . Cells with lower levels of IL-2R~ expression as compared with NK cells were still present after anti-IL-2R,8 mAb treatment (Fig. 2 B) . This cell population most likely represents CD8 + T, cells, since it lacks NKI.1 antigen expression. Asialo-GM1 + IL-2RB + cells were also depleted in anti-IL-2RB mAb-treated SCID mice (data not shown).
Further investigation revealed that the depletion was NK cell specific. First, similar numbers of cells were recovered from the spleen of anti-IL-2RB mAb-or control IgG-treated mice, and various splenic lymphocytes subsets remained intact in the mice treated with anti-IL-2R~ mAb (Table 1) . Second, lymphocyte composition in the thymus and lymph nodes were unaffected, and intraepithelial T cells, such as Thy-1 + dEC and intestinal intraepithelial T cells, were also unchanged by this anti-IL-2R~ mAb treatment (data not shown). Third, as shown in Fig. 3 , alloantigen-reactive CTL were induced normally from the spleen of anti-IL-2RB mAbtreated mice. Next we performed flow cytometric analysis at various time points after the single mAb treatment to determine the duration of the NK cell depletion. As shown in Fig. 4 , NKI.1 + IL-2RB + NK cells were hardly detectable in the spleen of the anti-IL-2RB-treated mice up to 5 wk after a single injection of the mAb, indicating that NK deficiency is long lasting. Ongoing experiment indicates that there is no sign of the recovery of NKI.I+IL-2RB + cells in the spleen even 7 wk after the mAb injection (data not shown). NK cell depletion in vivo was also successfully accomplished by administering antibody to cell surface antigens expressed in NK cells, such as asialo-GM1 (18), NKI.1 (19, 20) , and 3. Effector / Target ratio ministration of anti-IL-2RB mAb prompted us to evaluate the effect of in utero or postnatal treatment with anti-IL-2RB mAb on NK cell development. In utero treatment was carried out by intraperitoneal injection of anti-IL-2RB mAb into pregnant C57BL/6 mice from day 12 of gestation until birth, and postnatal treatment was by subcutaneous injection of the mAb to neonatal mice three times a week, which was continued until analysis. Cytolytic activity of NK cells in antibody-treated mice was determined at 6 wk of age.
As shown in Fig. 5 , the in utero treatment with anti-IL-2RB mAb did not reduce cytolytic activity of NK cells (Fig.  5 A) , whereas the postnatal treatment with the same mAb completely abrogated cytotoxicity of NK cells against YAC-1 cells (Fig. 5 B) . Flow cytometric analysis revealed that the in utero treatment did not alter development of NK cells in the spleen, whereas the postnatal treatment abolished the appearance of NK cells (data not shown). As previously described (7), the in utero treatment with the anti-IL-2RB mAb completely abrogated development of Thy-1 + dEC, whose precursor is IL-2R3 + fetal V75TCR § cells, indicating that this treatment made saturating levels of anti-IL-2R3 available in the fetal circulation during embryogenesis. These findings altogether suggest that NK cell and/or NK precursor cells become sensitive to anti-IL-2R3 treatment after birth.
Differential susceptibility of fetal and postnatal NK cells to anti-IL-2R3 mAb may suggest that induction or upregulation of IL-2R~ expression in the NK cell is a later event in the course of NK cell development. In fact, our preliminary experiments showed that murine fetal liver of gestation day 14 contains a small proportion of NKI.1 + cells that express considerably low levels of IL-2R~ as compared with adult NKI.1 + cells (T. Tanaka, unpublished observation). Recently, it was proposed that NK and T cells have a common origin (22) (23) (24) (25) . If NK and T cells do share the common pathway of development, the IL-2R~ + cells found in fetal liver may be one of the candidates of the "NK cell-T cell progenitor" Further biochemical and genetic studies are needed to elucidate the biological relevance of this cell population in NK cell and T cell development.
In the present study, we demonstrated a selective and longlasting elimination of NK cells by a single intraperitoneal injection of anti-IL-2RB mAb. The IL-2RB mAb may also help to generate animal models to which various types of human cells can be readily transplanted. Although SCID mice have been used for this purpose, it has been reported that a considerable proportion of human tumors actually fail to grow in SCID mice (26) possibly due to the NK activity observed in these mice (27, 28) . We have observed that pretreatment of SCID mice with anti-IL-2RB mAb indeed favored the growth of freshly isolated adult T cell leukemia cells in vivo (29) . Therefore, we believe that anti-IL-2RB mAb will afford the means of effectively manipulating NK cells in vivo.
